Cadre Holdings, Inc. (CDRE) stock
CDRENYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 15/3015% above fair value
$33.42+0.34 (+1.03%)
Close on Nov 13, 2026Market cap $1.43BP/E 36.7Yield 1.14%
Cadre r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $11.40M, up 36.0% from the year before. The highest annual figure on record is $11.40M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.40M | +36.0% |
| FY2024 | Dec 31, 2024 | $8.38M | +20.5% |
| FY2023 | Dec 31, 2023 | $6.95M | -1.9% |
| FY2022 | Dec 31, 2022 | $7.09M | +9.7% |
| FY2021 | Dec 31, 2021 | $6.46M | +14.7% |
| FY2020 | Dec 31, 2020 | $5.63M | – |
See a number that looks wrong?